Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

ClinicalTrials.gov ID: NCT02896101

Public ClinicalTrials.gov record NCT02896101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (Pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD).

Study identification

NCT ID
NCT02896101
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Enrollment
755 participants

Conditions and interventions

Interventions

  • Pimecrolimus Cream, 1% Drug
  • Elidel® (pimecrolimus) Cream Drug
  • Placebo of Pimecrolimus Cream, 1% Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2016
Primary completion
May 31, 2017
Completion
May 31, 2017
Last update posted
Jul 30, 2019

2016 – 2017

United States locations

U.S. sites
27
U.S. states
11
U.S. cities
22
Facility City State ZIP Site status
Investigational Site 4 Hot Springs Arkansas
Investigational Site 22 Little Rock Arkansas
Investigational Site 20 Anaheim California
Investigational Site 13 Fremont California
Investigational Site 26 Norco California
Investigational Site 17 Doral Florida
Investigational Site 9 Hialeah Florida
Investigational Site 16 Miami Florida
Investigational Site 18 Miami Florida
Investigational Site 19 Miami Florida
Investigational Site 25 Miami Florida
Investigational Site 8 Miami Florida
Investigational Site 12 North Miami Beach Florida
Investigational Site 3 Ormond Beach Florida
Investigational Site 7 South Miami Florida
Investigational Site 10 Tampa Florida
Investigational Site 24 Tampa Florida
Investigational Site 14 West Palm Beach Florida
Investigational Site 1 Arlington Heights Illinois
Investigational Site 21 Lake Charles Louisiana
Investigational Site 2 Silver Spring Maryland
Investigational Site 11 Saint Joseph Missouri
Investigational Site 27 East Windsor New Jersey
Investigational Site 5 High Point North Carolina
Investigational Site 23 Raleigh North Carolina
Investigational Site 15 Cincinnati Ohio
Investigational Site 6 Nashville Tennessee

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02896101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2019 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02896101 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →